FDA's New OTC Drugs Director Ganley Brings Cardio-Renal Background To Job
This article was originally published in The Tan Sheet
Executive Summary
Charles Ganley, MD, the new director of FDA's Division of OTC Drugs, brings to the post a background as an agency medical reviewer in the Division of Cardio-Renal Drug Products, where he has worked since 1989. He will report to Office of Drug Evaluation V Director Robert DeLap, MD/PhD.